All Categories
    Filters
    Preferences
    Search Results

    PARI LC Spirt & Plus Reusable Nebulizer Set

    PARI LC PLUS and LC Sprint reusable nebulizers combine small, consistent particles and fast treatments for targeted drug delivery to the lungs.
    *

    The PARI LC PLUS and LC Sprint reusable nebulizers

    • Combine small, consistent particles and fast treatments for targeted drug delivery to the lungs.
    • Maximizes aerosol delivery for respiratory therapy
    • Minimizes medication waste with Breath Enhanced Technology delivers more medication when you breathe in, and wastes less when you breath out
    • PARI nebulizers provide efficient aerosol therapy to help improve quality of life for patients of all ages
    • Trusted by pharmaceutical companies in more clinical trials than any other brand
    • Pari LC Plus used Primarly for Tobi Medication, along with other medications 
    • Pari LC Spirnt used with all other Medications, not Tobi Medication

    Care: rinse after each use with warm water. mild soap. Dishwasher or boiled water nightly for optimal perdivance and care. Replace at 6 months or sooner as needed.

    What's Included: Your Choice of LC PLUS or LC Sprint Reusable Nebulizer, valved mouthpiece, Wing Tip tubing, and Instructions for Use.

    Perdivance with PARI LC Sprint

    • Total Output Rate: 500 mg/min
    • MMD (Mass Median Diameter) 3.5 um
    • %RF (Mass Percentage <5 u): 68%
    • Average Treatment time: ~5 minutes

    Perdivance with PARI LC PLUS: Considered the “GOLD Standard” in nebulizer therapy for the treatment of diseases such as asthma, COPD and Cystic Fibrosis, its integrated valve system maximizes drug delivery upon inhalation and minimizes drug loss during exhalation

    • Total Output Rate: 440 mg/min
    • MMD (Mass Median Diameter) 3.8 um
    • %RF (Mass Percentage <5 u): 65%
    • Average Treatment time: 6-7 minutes

    Both PARI LC PLUS and LC Sprint deliver more drug in less time compared to Sidestream Plus.

    PARI Reusable Nebulizers were used in the following clinical trials to prove safety and efficacy:

    Pulmicort Respules - AstraZeneca TOBI, Yupelri, Perforomist, Accuneb,and Duoneb - Mylan

    Pulmozyme - Genentech Xopenex and Brovana - Sunovion